One of our clients published preclinical data on NASH-fibrosis on NPJ Precision Oncology
We announced that a study in the STAM™ mouse model of NASH performed by SMC Laboratories Inc. has been published in NPJ Precision Oncology by Genentech, Inc.:
Title: “Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology”
This study reported that treatment of TGF-β neutralizing antibody in the STAM™ mouse model ameliorated the fibrotic environment could facilitate redistribution of CD8+ lymphocytes into tumors. These results provide a strong rationale for utilizing immunotherapies in HCC earlier during treatment, potentially in combination with anti-fibrotic therapies.
The STAMTM mouse model can be used in the pharmacology studies of the immune-oncology field.